Actively Recruiting
Korean Vascular Intervention Society Multicenter Registry Study on Outcomes of Endovascular Therapy in Lower Limb Artery Diseases (K-VIS ELLA): (A Retrospective & Prospective Observational Study)
Led by Yonsei University · Updated on 2025-04-30
12000
Participants Needed
1
Research Sites
982 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
1. Study design: multicenter retrospective and prospective observational study 2. Study Cohort : 1. Retrospective cohort: This cohort retrospectively enrolls patients with lower extremity artery disease who underwent endovascular treatment from January 2006 to the date of approval by IRB in the participating hospitals. Informed consent was waived by IRB. 2. Prospective cohort: This cohort prospectively enrolls patients with lower extremity artery disease who undergo endovascular treatment from the date of approval by IRB to July, 2018 in the participating hospitals. Informed consent will be obtained prior to enrollment. 3. Baseline clinical and lesion characteristics, procedural and post-procedural data, clinical outcomes, hemodynamic, and imaging follow-up data are investigated. Primary patency and target lesion revascularization rates of the total cohort and patient subgroups are evaluated. Risk factors of restenosis and target lesion revascularization are determined.
CONDITIONS
Official Title
Korean Vascular Intervention Society Multicenter Registry Study on Outcomes of Endovascular Therapy in Lower Limb Artery Diseases (K-VIS ELLA): (A Retrospective & Prospective Observational Study)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients who underwent or attempted endovascular treatment for symptomatic peripheral artery disease from January 2006 until IRB approval date (retrospective cohort)
- Age 20 years or older (prospective cohort)
- Patients treated or attempting treatment for symptomatic peripheral artery disease from IRB approval date (prospective cohort)
- Symptomatic peripheral artery disease including intermittent claudication (Rutherford category 1 to 3) or critical limb ischemia (Rutherford category 4 to 6)
You will not qualify if you...
- Pregnant women or women with potential childbearing
- Moderate Alzheimer's disease, mental illness, or neurological disease impairing understanding of the study
- Life expectancy less than 1 year due to other medical conditions
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Severance Hospital
Seoul, South Korea, 120-752
Actively Recruiting
Research Team
Y
Young-Guk Ko, PhD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here